Anupam Rasayan India Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹512Cr
- +31.3% YoY
- −30% QoQ
- Net profit
- ₹61Cr
- +13% YoY
- +7% QoQ
- Margin
- 25%
- −7 pp YoY
- +6 pp QoQ
Guidance rank: #22 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.
From Anupam Rasayan India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum.
- Management optimistic about continuing growth into FY27, driven by robust pipeline and deepening global customer relationships.
- Expansion supported by scaling up commercial molecules and ramping up capacity utilization.
- Focus on ramping up Pharma and Performance Material portfolios, which showed significant growth (Pharma up 85%, Performance Materials up 245% YoY for 9MFY26).
- Pipeline includes 65+ molecules in R&D/pilot stages, supporting future revenue growth.
- Acquisition of Jayhawk Fine Chemicals to strengthen North America footprint, expanding access to innovation-driven sectors (semiconductors, automotive, pharma, EV).
2 more points from Anupam Rasayan India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- It highlights the strategic acquisition of Jayhawk Fine Chemicals, a US-based specialty chemicals company, expected to close soon, which represents a significant capital investment expanding Anupam's footprint in the US.
- This acquisition strengthens supply chain presence, technology, customer base, and product portfolio across high-value sectors like semiconductors, pharma, EV, and aerospace.
- The company also focuses on ramping up capacity utilization across manufacturing assets and smoothly integrating Jayhawk, implying ongoing investments in operational expansion.
- The management emphasizes growth driven by expanding global footprints, pipeline commercialization, and technology enhancement, indicating possible capex aligned with these goals going forward.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- In 9MFY26, Letters of Intent (LOIs) and contracts contributed over INR 250 crores of revenue, indicating strong conversion of the order pipeline into commercial revenue.
- The company has a robust pipeline with over 65 molecules across R&D and pilot stages in Pharma and Polymer segments.
- The Pharma segment has more than 30 molecules under development and pilot stages.
2 more points from Anupam Rasayan India Ltd's call on order book
Create a free account to keep reading this call
Anupam Rasayan India Ltd — Quarterly revenue & net profit
Anupam Rasayan India Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 512 | 390 | +31.3% | 731 | -30% |
| Operating profit (EBITDA) | 127 | 124 | +2.4% | 136 | -6.6% |
| Operating margin | 25% | 32% | -7 pp | 19% | +6 pp |
| Profit before tax | 60 | 59 | +1.7% | 76 | -21.1% |
| Net profit (PAT) | 61 | 54 | +13% | 57 | +7% |
| EPS (₹) | 4.31 | 2.56 | +68.4% | 3.90 | +10.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹806 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anupam Rasayan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anupam Rasayan India Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anupam Rasayan India Ltd Q3 FY26 results?
Q3 9MFY26 revenue grew 84% YoY to INR 1,730 crores, indicating strong growth momentum. Anupam Rasayan expects continued growth momentum into FY27, supported by a strong pipeline, deeper customer relationships, and expanding global footprints.
What is Anupam Rasayan India Ltd share price analysis?
Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
